Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.
open access to scientific and medical research
From submission to first editorial decision.
From editorial acceptance to publication.
The a
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
The product's debut marks a revolutionary all-in-one greens with the postbiotic IMMUSE™ for immune system support.
Glaxon™, producer of sports nutrition dietary supplements, has just released a new product in the greens supplement category. SuperGreens Enhanced Immune Edition c
The product's debut marks a revolutionary all-in-one greens with the postbiotic IMMUSE™ for immune system support.
Glaxon™, producer of sports nutrition dietary supplements, has just released a new product in the greens supplement category. SuperGreens Enhanced Immune Edition c
Published: Jul 22, 2022 By Mark Terry
BioSpace is excited to introduce FDA Weekly Review, a column that looks at the U.S. Food and Drug Administration’s actions related to drug approvals, IND approvals, Breakthroug
New Jersey, USA,- The Global L-Proline Market research offers a thorough analysis of the market throughout the course of the projection period. The study includes a number of sections as well as an examination of the occasions and elements that are most likely to have a major impact in th
Latest Update: This has brought along several changes this report also covers the impact of Current COVID-19 situation
The rising technology in Acetyl Tyrosine Market is also depicted in this research report. Factors that are boosting the growth of the market, and giving a positive p
Tecartus ® (Brexucabtagene Autoleucel) First and Only CAR T in Europe to Receive Positive CHMP Opinion to Treat Adults 26+ with rr ALL –
– If Approved, it will Address a Significant Unmet Need for a Patient Population with Limited Treatment Options –
Kite, a Gilead Compa
Tecartus ® (Brexucabtagene Autoleucel) First and Only CAR T in Europe to Receive Positive CHMP Opinion to Treat Adults 26+ with rr ALL –
– If Approved, it will Address a Significant Unmet Need for a Patient Population with Limited Treatment Options –
Kite, a Gilead Compa
By continuing to browse our site you agree to our Privacy & Cookie Policy. > Privacy & Cookie Policy I Agree
22 Jul 2022 --- This week in industry news, M